Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we�…

Although T lymphocytes have long been appreciated for their role in the immunosurveillance
of cancer, it has been the realization that cancer cells may ultimately escape a response�…

Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy�…

Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced
algorithms to identify drivers now exist, but systematic attempts to combine and optimize�…

Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about�…

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint
inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of�…

Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-
1) in human melanoma, most patients do not experience durable clinical benefit. Pre�…

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an
exciting era of anticancer therapy. Durable responses can be seen in patients with�…

PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely�…

The FDA approved pembrolizumab on June 16, 2020, for the treatment of adult and pediatric
patients with unresectable or metastatic tumor mutational burden–high [TMB-H;≥ 10�…